

# Guido Stirnimann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8831095/publications.pdf>

Version: 2024-02-01

43  
papers

647  
citations

567281  
15  
h-index

610901  
24  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1107  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, 820724.   | 3.5 | 22        |
| 2  | Consensus care recommendations for alfa-pump® in cirrhotic patients with refractory or recurrent ascites. <i>BMC Gastroenterology</i> , 2022, 22, 111.  | 2.0 | 5         |
| 3  | Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump. <i>Liver International</i> , 2022, 42, 2247-2259.  | 3.9 | 4         |
| 4  | Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. <i>Journal of Autoimmunity</i> , 2021, 116, 102578.   | 6.5 | 17        |
| 5  | Determination of bile acids from human gallbladder by 1 H-MRS Protocol optimization and estimation of reproducibility. <i>NMR in Biomedicine</i> , 2021, 34, e4432.   | 2.8 | 2         |
| 6  | Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.   | 3.9 | 5         |
| 7  | Aspects of albendazole metabolism in western lowland gorillas ( <i>Gorilla gorilla gorilla</i> ) compared to humans and other species assessed by HPLC, LC-MS, and chiral electrokinetic chromatography. <i>Separation Science Plus</i> , 2021, 4, 347-356. | 0.6 | 0         |
| 8  | P041 Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .  |     | 1         |
| 9  | Treatment of refractory ascites with an automated low flow ascites pump in patients awaiting liver transplantation. <i>Journal of Liver Transplantation</i> , 2021, 4, 100037.  | 0.4 | 2         |
| 10 | Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study. , 2021, 59, .                       |     | 1         |
| 11 | Management of transthyretin amyloidosis. <i>Swiss Medical Weekly</i> , 2021, 151, w30053.   | 1.6 | 7         |
| 12 | Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1151-1158.  | 3.9 | 17        |
| 13 | Transjugular intrahepatic portosystemic shunt and alfa-pump® system for refractory ascites in liver cirrhosis: Outcomes and complications. <i>United European Gastroenterology Journal</i> , 2020, 8, 961-969.  | 3.8 | 8         |
| 14 | Tailored access to the hepatobiliary system in post-bariatric patients: a tertiary care bariatric center experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 5469-5476.   | 2.4 | 8         |
| 15 | Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis. <i>Hepatology</i> , 2020, 71, 2135-2148.  | 7.3 | 46        |
| 16 | Hyper-coagulability in obese patients accurately identified by combinations of global coagulation assay parameters. <i>Thrombosis Research</i> , 2020, 187, 91-102.   | 1.7 | 10        |
| 17 | Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. <i>Swiss Medical Weekly</i> , 2020, 150, w20364.  | 1.6 | 10        |
| 18 | Mental Illness Has a Negative Impact on Weight Loss in Bariatric Patients: a 4-Year Follow-up. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 232-238.  | 1.7 | 14        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | First Clinical Case of In Vivo Acquisition of DHA-1 Plasmid-Mediated AmpC in a Salmonella enterica subsp. enterica Isolate. Antimicrobial Agents and Chemotherapy, 2019, 63, .   | 3.2 | 8         |
| 20 | Nutritional Challenges in Patients with Advanced Liver Cirrhosis. Journal of Clinical Medicine, 2019, 8, 1926.   | 2.4 | 18        |
| 21 | Cirrhosis and Autoimmune Liver Disease. Current Hepatology Reports, 2019, 18, 49-58.   | 0.9 | 0         |
| 22 | Adipopenia correlates with higher portal pressure in patients with cirrhosis. Liver International, 2019, 39, 1672-1681.  | 3.9 | 26        |
| 23 | Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites. BMC Palliative Care, 2019, 18, 109.  | 1.8 | 9         |
| 24 | Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e129-e131.           | 2.4 | 8         |
| 25 | Recurrent and De Novo Autoimmune Hepatitis. Liver Transplantation, 2019, 25, 152-166.  | 2.4 | 59        |
| 26 | Limited performance of subjective global assessment compared to computed tomography-determined sarcopenia in predicting adverse clinical outcomes in patients with cirrhosis. Clinical Nutrition, 2019, 38, 2696-2703. | 5.0 | 32        |
| 27 | Letter: innovative use of the alfapump system to treat small hepatocellular carcinoma – authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 696-697.   | 3.7 | 0         |
| 28 | Reply to: The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thrombosis Research, 2018, 164, 15-16.  | 1.7 | 3         |
| 29 | C-Reactive Protein on Postoperative Day 1: a Predictor of Early Intra-abdominal Infections After Bariatric Surgery. Obesity Surgery, 2018, 28, 2760-2766.  | 2.1 | 17        |
| 30 | Geoeidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Clinical Reviews in Allergy and Immunology, 2018, 54, 295-306.  | 6.5 | 12        |
| 31 | Editorial: alfapump – an alternative to large-volume paracentesis for patients with refractory ascites? Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 140-141.                                   | 3.7 | 0         |
| 32 | Effect of Rivaroxaban on thrombin generation in vivo. A study in obese patients. International Journal of Laboratory Hematology, 2018, 40, e11-e14.  | 1.3 | 14        |
| 33 | Should Sarcopenia Increase Priority for Transplant or Is It a Contraindication?. Current Gastroenterology Reports, 2018, 20, 50.   | 2.5 | 12        |
| 34 | Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology, 2018, 53, 1114-1120.                       | 1.5 | 41        |
| 35 | The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. Surgery for Obesity and Related Diseases, 2018, 14, 1890-1896.  | 1.2 | 31        |
| 36 | Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. Hepatology Communications, 2018, 2, 933-944.  | 4.3 | 21        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Treatment of Malignant Ascites Using an Automated Pump Device. American Journal of Gastroenterology, 2018, 113, 1060-1061.  | 0.4 | 4         |
| 38 | Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. British Journal of Clinical Pharmacology, 2017, 83, 1466-1475. | 2.4 | 48        |
| 39 | Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites. Therapeutic Advances in Gastroenterology, 2017, 10, 283-292.                               | 3.2 | 32        |
| 40 | Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2017, 46, 981-991.                            | 3.7 | 46        |
| 41 | Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. Journal of Viral Hepatitis, 2016, 23, 697-707.                                     | 2.0 | 3         |
| 42 | Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations. PLoS ONE, 2016, 11, e0164443.   | 2.5 | 7         |
| 43 | Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy, 2014, 15, 2609-2622.  | 1.8 | 17        |